Abbott’s HUMIRA® (Adalimumab) Approved In The European Union For The Treatment Of Crohn’s Disease
Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA® (adalimumab) as a treatment for severe Crohn’s disease. HUMIRA is the first self-administered biologic for the treatment of Crohn’s disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease.
